Cutaneous side effects of oral corticosteroid therapy
DOI:
https://doi.org/10.66344/jpad.v15i1.613Keywords:
Oral steroids, infections, atrophy, moon face, buffalo humpAbstract
Background Corticosteroids revolutionized the treatment of many skin disorders during 5th
and 6th decades of last century. They have anti inflammatory, vasoconstrictor,
antiproliferative and immunosuppressive effects.
Objective The study was aimed to determine the frequency of cutaneous changes in patients
on oral steroids and to see the pattern of these changes in our population.
Material and methods The study was carried out in the department of dermatology, Civil
Hospital, Karachi. 204 patients fulfilling the inclusion criteria completed in the study. All the
patients were taking 60-80mg of oral steroids for a minimum of 2 weeks. Findings were
recorded on a preformed pro forma. Any relevant investigations were also carried out.
Results were then compiled and tabulated.
Results Multiple cutaneous infections was the most common side effect seen in 45 patients
(22%, p>0.10). Moon face was seen in 39 patients (19%, p<0.001) and buffalo hump in 17
patients (8.3%, p>0.08). Atrophic changes were a feature in 45 patients (22.5%, p>0.47).
Other findings seen in our patients were acneiform eruptions in 18 patients (8.7%, p<0.001)
and hypertrichosis in 8 patients (4%, p>0.013).
Conclusion Oral steroid therapy is associated with significant cutaneous side effects which
depend on the dose and duration of therapy. Bacterial infections remain the most common
side effect.
References
1. Chosidow O, Lebrun-Vignes B, Bourgault-Villada I. Local corticosteroid therapy in dermatology. Press Medic 2000; 28: 2050-6.
2. Seale JP, Compton MR. Side effects of corticosteroid agents. Med J Aust 1986; 144: 139-42.
3. Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in patients taking glucocorticoids. Reviews Infect Dis 1989; 11: 954-63.
4. Akhter SJ, Manzoor-ul-Hasan. Treatment of pemphigus, a local experience. J Pak Med Assoc 1989; 48: 300-4.
5. Twycross R. The risks and benefits of corticosteroids in advanced cancer. Drug Safety 1994; 11: 163-78.
6. Sun-YN, Mckay LI, Dubois DC et al. Pharmacokinetic/ pharmacodynamic models for corticosteroid receptor down regulation and glutamine synthetase induction in rat skeletal muscle by a receptor/ gene mediated mechanism. J Pharmacol Exp Ther 1999; 28: 720-8.
7. Schwartz E, Mezick JA, Gendimenico GJ, Kligman LH. In vivo prevention of corticosteroid-induced skin atrophy by tretinoin in the hairless mouse is accompanied by modulation of collagen, glucoseaminoglycans and fibronectin. J Invest Dermatol 1994; 102: 241-6.
8. Mc Micheal AJ, Griffiths CE, Talwar HS et al. Concurrent application of tretinoin (retinoic acid) partially protects against corticosteroid induced epidermal atrophy. Br J Dermatol 1996; 135: 164.
9. Lubach D, Hinze E. Development and regression of dermal corticosteroid atrophy change in skin fold and thickness. Occup Environ Dermatoses 1986; 34: 146-9.
10. Soerma S, Lassus A, Salde L. Assessment of atrophy of human skin caused by corticosteroids using chamber occlusion blister techniques. Acta Derm Venereol 1984; 64: 41-5.
11. Zheng PS, Lavker RM, Lehman P, Kligman AM. Morphologic investigation in the rebound phenomenon after corticosteroid induced atrophy in human skin. J Invest Dermatol 1984; 82: 345-52.
12. Evans NA. Gym and toxic: A profile of
100 male steroid users. Br J Sports Med 1997; 31: 54-8.
13. Precious DS, Hoffman CD, Milter R. Steroid acne after orthognathic surgery. Oral Surg Oral Med Oral Path 1992; 74: 279-81.
14. Samma S, Yoshikawa M, Futami T et al. Corticosteroid as an antiemetic agent in cancer chemotherapy with cis diammine dichloroplatinum. J Cancer Chemo 1985; 12: 561-5.
Downloads
Published
Issue
Section
License
Copyright (c) 2016 Sarwat Nasreen, Zarnaz Wahid, Ijaz Ahmed
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
